John B. KisielSpringer New YorkAhlquist DA, Kisiel JB. Stool DNA for colorectal cancer screening: from concepts to quality care. In: Shaukat A, Allen JI, eds. Colorectal Cancer Screening: Quality and Benchmarks. New York, NY: Springer; 2015:97-112....
Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022;19(8):521-531. doi:10.1038/s41575-022-00612-yPubMedGoogle ScholarCrossref 7. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer ...
The Stool DNA Test: An Emerging Technology in Colorectal Cancer ScreeningGreenwald, Beverly PhD, RN, CNS, CGRN Abstract The stool DNA test is considered an emerging technology in screening for colorectal cancer. The stool DNA test detects DNA markers which are shed from cells of ...
6 Screening strategies should therefore include a standard screening method to detect precancerous lesions in asymptomatic individuals, identifying those eligible for screening by risk assessment.6, 7 Increased knowledge on specific changes and molecular pathways underlying CRC malignancy has led to the ...
下载 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。温馨提示:该文献已被科研通 学术中心 收录,前往查看 科研通『学术中心』是文献索引库,收集文献的基本信息(如标题、摘要、期刊、作者、被引量等),不提供下载功能。如需下载文献全文,请通过文献求助获取。上...
(HealthDay)—Tests for blood in the stool can consistently detect colon cancer when used on an annual basis, and they are effective even in the second, third and fourth years of screening, a new study says.
The test screens for early signs of colon cancer and checks for blood in the stool. The EZ Detect Stool Blood Test costs $6-$10 at various retail outlets. It checks the stool sample for blood which can be an indicator of bleeding ulcers, hemorrhoids, polyps, colitis or cancer. ...
colorectal cancer for serology hemoglobin fecal occult blood rapid diagnostic test Hema-Screen® Result display time: 2 min ... collect and test specimens for signs of Occult Blood - an early sign of colorectal cancer. The assay is performed in the laboratory and utilizes on-slide positive...
Layoffs Turnstone Biologics to Lay Off 60% of Workforce, Overhaul C-Suite October 11, 2024 · 2 min read · Angela Gabriel IPO Upstream Raises $255M IPO for Inflammatory Drugs; CAMP4 Nets $75M for RNA Work October 11, 20...
Colorectal cancer (CRC) screening continues to be underutilized in the USA despite the availability of multiple effective, guideline-recommended screening options. Provider recommendation has been consistently shown to improve screening completion. Understanding how patient-provider communication influences CRC...